Donepezil Hydrochloride
Product Images NDC 63629-1117

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-1117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lbl636291117

Label for donepezil hydrochloride tablets, USP 23 mg, by Bryant Ranch Prepack. The label shows the dosage strength 23 mg prominently in black text within a red box. It includes storage instructions, child-resistant packaging information, and a note to keep medication out of children's reach. The package contains 30 tablets and is labeled Rx only with NDC 63629-1117-1.*

FDA Label Image

Structural Formula (Spl Image1 Structure)

Chemical structure of donepezil hydrochloride showing its molecular components including aromatic rings, ether groups, piperidine ring, and hydrochloride moiety.*

FDA Label Image

Figure 9 (Spl Image10 Figure9)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months of treatment, comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis measures score change, with clinical improvement and decline indicated, while the x-axis shows months of drug treatment. Donepezil shows less clinical decline than placebo over time.*

FDA Label Image

Figure 10 (Spl Image11 Figure10)

A line graph depicting the cumulative percentage of patients against ADCS-ADL change from baseline for donepezil hydrochloride 10 mg/day compared to placebo. The graph shows two curves, one for donepezil hydrochloride and one for placebo, illustrating patient response differences over a range of baseline changes.*

FDA Label Image

Figure 11 (Spl Image12 Figure11)

A line graph showing the change from baseline in SIB (Severe Impairment Battery) scores over 24 weeks of drug treatment for donepezil hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis represents weeks of treatment, while the y-axis shows SIB change from baseline with markers for clinical improvement and decline. The 23 mg/day dose shows greater improvement compared to 10 mg/day.*

FDA Label Image

Figure 12 (Spl Image13 Figure12)

A cumulative percentage plot showing patients' responses to Donepezil HCl at 23 mg/day and 10 mg/day. The x-axis represents SIB (Severe Impairment Battery) change from baseline, and the y-axis represents the cumulative percentage of patients. The graph compares efficacy at the two dosage levels.*

FDA Label Image

Figure 13 (Spl Image14 Figure13)

A bar chart comparing the percentage of patients experiencing different levels of CIBIC-plus ratings for Donepezil Hydrochloride at 23 mg/day versus 10 mg/day. Categories range from Markedly Improved to Markedly Worse, showing patient response distribution for each dosage level.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line chart depicting ADAS-cog change from baseline over 30 weeks comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis shows mean change with standard error from baseline, indicating clinical improvement or decline, while the x-axis shows weeks of drug treatment and placebo period. Data points for each treatment group are traced showing effectiveness trends over time.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A cumulative percentage of patients line graph showing change from baseline in ADAS-cog scores for donepezil hydrochloride at 5 mg/day and 10 mg/day doses, compared to placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes data points for placebo, 5 mg/day, and 10 mg/day treatment groups.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A bar graph displaying patient response percentages to Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo across categories from markedly improved to markedly worse. The x-axis shows response levels, and the y-axis shows the percentage of patients. Donepezil 10 mg/day shows higher improvement and less worsening compared to placebo.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph showing ADAS-cog change from baseline (mean ± SE) over weeks of drug treatment up to week 12, with an additional placebo measurement at week 15. The graph compares three groups: Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis indicates clinical improvement (negative values) to clinical decline (positive values), with both doses of Donepezil showing improvement relative to placebo.*

FDA Label Image

Figure 5 (Spl Image6 Figure5)

A cumulative percentage graph showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride at 5 mg/day, 10 mg/day, and placebo groups. The x-axis represents change from baseline in points, and the y-axis represents the cumulative percentage of patients. The graph includes markers at 7 points, 4 points, and no change, with a table summarizing percentage changes in each treatment group.*

FDA Label Image

Figure 6 (Spl Image7 Figure6)

A bar chart comparing the percentage of patients experiencing different levels of improvement or worsening in response to Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. Categories on the x-axis include markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse, with percentages on the y-axis.*

FDA Label Image

Figure 7 (Spl Image8 Figure7)

A line chart showing SIB change from baseline over 6 months of drug treatment. The chart compares donepezil hydrochloride 10 mg/day to placebo, illustrating clinical improvement for donepezil and clinical decline for placebo over time. Error bars indicate standard error.*

FDA Label Image

Figure 8 (Spl Image9 Figure8)

A cumulative percentage of patients graph depicting SIB (Severe Impairment Battery) change from baseline. It compares donepezil hydrochloride 10 mg/day with placebo, showing progression in cognitive function scores over varying degrees of baseline change.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.